Freeline Therapeutics Holdings plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRLN research report →
About the company
Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males.
- CEO
- Michael J. Parini
- IPO
- 2020
- Employees
- 152
- HQ
- Stevenage, GB
Price Chart
- Market Cap
- $28.28M
- P/E
- -0.29
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -102.94%
- ROIC
- -168.75%
- Revenue
- $0 · 0.00%
- Net Income
- $-88,972,000 · 36.63%
- EPS
- $-22.52 · 61.82%
- Op Income
- $-98,447,000
- FCF YoY
- 23.78%
- 52W High
- $8.74
- 52W Low
- $2.11
- 50D MA
- $6.40
- 200D MA
- $4.57
- Beta
- 0.66
- Avg Volume
- 28.14K
Get TickerSpark's AI analysis on FRLN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our FRLN coverage
Recent articles, reports, and earnings notes.
No research on FRLN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FRLN report →Similar companies
Peers in the same neighborhood.